Cargando…

Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis

BACKGROUND: Omalizumab has been approved for treating moderate-to-severe asthma in children aged over 6 years. Its application to asthmatic children with other allergic diseases has been rarely explored. The present study aims to explore the therapeutic efficacy of omalizumab in children with modera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chong, Weikun, Li, Hailang, Wang, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Allergy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613665/ https://www.ncbi.nlm.nih.gov/pubmed/37908372 http://dx.doi.org/10.3389/falgy.2023.1236798

Ejemplares similares

280 Use of Omalizumab in Chronic Moderate to Severe Persistent Asthma-an Indian Experience
por: Ansari, Qamar, et al.
Publicado: (2012)

Efficacy and safety of omalizumab therapy in urticaria vasculitis
por: Petrelli, Fiorella, et al.
Publicado: (2022)

155 Omalizumab Improves Asthma but not Nasal Symptoms in Japanese Patients With Severe Allergic Asthma and Rhinitis
por: Nishihara, Fuyumi, et al.
Publicado: (2012)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Impact of Therapeutics on Unified Immunity During Allergic Asthma and Respiratory Infections
por: Flores-Torres, Armando S., et al.
Publicado: (2022)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab Reduces Unplanned Healthcare Interactions in Irish Patients With Chronic Spontaneous Urticaria
por: Ridge, Katie, et al.
Publicado: (2021)

Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
por: García-Gómez, Elizabeth, et al.
Publicado: (2022)

Immunogenetics and pharmacogenetics of allergic asthma in Africa
por: Mabelane, Tshegofatso, et al.
Publicado: (2023)

277 Serum Soluble Trail Levels in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

New Insights on the Role of pentraxin-3 in Allergic Asthma
por: Koussih, Latifa, et al.
Publicado: (2021)

Severe exercise-induced anaphylaxis in a hot and humid area successfully treated with omalizumab: a case report
por: Mobayed, Hassan, et al.
Publicado: (2023)

Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma
por: Zafari, Zafar, et al.
Publicado: (2016)

282 Successful Treatment of Severe Nonallergic Asthma by Omalizumab. An Observation
por: Bergmann, Karl-Christian, et al.
Publicado: (2012)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Deletion of Miro1 in airway club cells potentiates allergic asthma phenotypes
por: Bruno, Sierra, et al.
Publicado: (2023)

276 A 4-Year Follow-up in Children With Moderate/Severe Asthma after Withdrawal 1 Year Omalizumab Treatment
por: Teijeiro, Alvaro, et al.
Publicado: (2012)

Translational Analysis of Moderate to Severe Asthma GWAS Signals Into Candidate Causal Genes and Their Functional, Tissue-Dependent and Disease-Related Associations
por: Portelli, Michael A., et al.
Publicado: (2021)

279 Near-Fatal Asthma Treated with Omalizumab
por: Contreras Contreras, Elvia Angelica, et al.
Publicado: (2012)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Poster 1014: Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis
por: Gonzalez-Diaz, Sandra Nora, et al.
Publicado: (2014)

Immunobiology of Steroid-Unresponsive Severe Asthma
por: Marshall, Courtney Lynn, et al.
Publicado: (2021)

Inflammatory Remission in T2 Severe Asthma
por: Rial, Manuel J., et al.
Publicado: (2022)

278 Total Antioxidant Capacity, Hydrogen Peroxide, Malondialdehyde and Total Nitric Oxide Concentrations in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Novel treatment of allergic fungal sinusitis using omalizumab
por: Evans, Martin Oman, et al.
Publicado: (2014)

COVID-19, Eosinophils, and Biologicals for Severe Asthma
por: Lombardi, Carlo, et al.
Publicado: (2022)

Purinergic Receptors in the Airways: Potential Therapeutic Targets for Asthma?
por: Thompson, Rebecca J., et al.
Publicado: (2021)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
por: Nishima, Sankei, et al.
Publicado: (2019)

Omalizumab for the treatment of severe allergic asthma in children: A tale of two
por: Brannick, Sinéad, et al.
Publicado: (2022)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study
por: Bhutani, Mohit, et al.
Publicado: (2017)

Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2019)

Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma
por: Hanania, Nicola A., et al.
Publicado: (2022)

Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population
por: O’Quinn, John, et al.
Publicado: (2014)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
por: D'Amato, Maria, et al.
Publicado: (2022)

Editorial: The impact of climate change on allergic disease
por: Aguilera, Juan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_squ6c9vaok9j51e4312c0hc9jb